Clinical Trial Update: PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating PDE5 inhibitor use and non-arteritic anterior ischemic optic neuropathy was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anterior Ischemic Optic Neuropathy

Drugs mentioned

• PDE5 inhibitor

Snippet

Sponsor: Bayer | Conditions: Anterior Ischemic Optic Neuropathy | Phase 4 | Status: TERMINATED | Results posted: 2019-01-23